<?xml version="1.0" encoding="UTF-8"?>
<snippetsTree>
 <snippets file="drugDebug/PMC7139247/results/search/disease/results.xml">
  <result pre="International Society of Chemotherapy. pmcid: 7139247S0924-8579(20)30101-1 doi: 10.1016/j.ijantimicag.2020.105951105951 : Article" exact="Coronavirus disease" post="2019 (COVID-19): current status and future perspectives LiHenga1LiuShang-Minga1YuXiao-Huab1TangShi-Lin286756823@qq.coma⁎⁎TangChao-Ketangchaoke@qq.coma⁎[a], [b],"/>
  <result pre="Society of Chemotherapy. pmcid: 7139247S0924-8579(20)30101-1 doi: 10.1016/j.ijantimicag.2020.105951105951 : Article Coronavirus" exact="disease" post="2019 (COVID-19): current status and future perspectives LiHenga1LiuShang-Minga1YuXiao-Huab1TangShi-Lin286756823@qq.coma⁎⁎TangChao-Ketangchaoke@qq.coma⁎[a], [b],"/>
  <result pre="- including this research content - immediately available in PubMed" exact="Central" post="and other publicly funded repositories, such as the WHO"/>
  <result pre="Central and other publicly funded repositories, such as the WHO" exact="COVID" post="database with rights for unrestricted research re-use and analyses"/>
  <result pre="M, E and N proteins. •Pangolin may be a potential" exact="intermediate" post="host for SARS-CoV-2. •Antiviral therapy, cellular therapy, immunotherapy and"/>
  <result pre="immunotherapy and Chinese medicine may be promising therapeutic strategies. Abstract" exact="Coronavirus disease" post="2019 (COVID-19) originated in the city of Wuhan, Hubei"/>
  <result pre="and Chinese medicine may be promising therapeutic strategies. Abstract Coronavirus" exact="disease" post="2019 (COVID-19) originated in the city of Wuhan, Hubei"/>
  <result pre="2019 (COVID-19) originated in the city of Wuhan, Hubei Province," exact="Central" post="China, and has spread quickly to 72 countries to"/>
  <result pre="date. COVID-19 is caused by a novel coronavirus, named severe" exact="acute" post="respiratory syndrome coronavirus 2 (SARS-CoV-2) [previously provisionally known as"/>
  <result pre="COVID-19 is caused by a novel coronavirus, named severe acute" exact="respiratory" post="syndrome coronavirus 2 (SARS-CoV-2) [previously provisionally known as 2019"/>
  <result pre="is caused by a novel coronavirus, named severe acute respiratory" exact="syndrome" post="coronavirus 2 (SARS-CoV-2) [previously provisionally known as 2019 novel"/>
  <result pre="aetiology, pathogenesis and epidemiological characteristics. Keywords COVID-19 SARS-CoV-2 2019-nCoV Coronavirus" exact="Pneumonia" post="Editor: Jean-Marc Rolain 1 Introduction Coronaviruses (CoVs) belong to"/>
  <result pre="whilst δ- and γ-CoVs infect birds. Two recent outbreaks of" exact="viral pneumonia" post="caused by β-CoVs are severe acute respiratory syndrome (SARS)"/>
  <result pre="δ- and γ-CoVs infect birds. Two recent outbreaks of viral" exact="pneumonia" post="caused by β-CoVs are severe acute respiratory syndrome (SARS)"/>
  <result pre="recent outbreaks of viral pneumonia caused by β-CoVs are severe" exact="acute" post="respiratory syndrome (SARS) and Middle East respiratory syndrome (MERS)."/>
  <result pre="outbreaks of viral pneumonia caused by β-CoVs are severe acute" exact="respiratory" post="syndrome (SARS) and Middle East respiratory syndrome (MERS). In"/>
  <result pre="of viral pneumonia caused by β-CoVs are severe acute respiratory" exact="syndrome" post="(SARS) and Middle East respiratory syndrome (MERS). In 2002,"/>
  <result pre="β-CoVs are severe acute respiratory syndrome (SARS) and Middle East" exact="respiratory" post="syndrome (MERS). In 2002, an outbreak of SARS was"/>
  <result pre="are severe acute respiratory syndrome (SARS) and Middle East respiratory" exact="syndrome" post="(MERS). In 2002, an outbreak of SARS was first"/>
  <result pre="likely originated from bats and then infected humans through other" exact="intermediate" post="animal hosts, e.g. the civet (Paguma larvata) for SARS-CoV"/>
  <result pre="[10]. Beginning in December 2019, a number of patients with" exact="pneumonia" post="of unknown aetiology emerged in Wuhan City, Hubei Province,"/>
  <result pre="pneumonia of unknown aetiology emerged in Wuhan City, Hubei Province," exact="Central" post="China. Genome sequencing has demonstrated that this pneumonia, named"/>
  <result pre="Central China. Genome sequencing has demonstrated that this pneumonia, named" exact="coronavirus disease" post="2019 (COVID-19), is caused by a novel CoV, namely"/>
  <result pre="China. Genome sequencing has demonstrated that this pneumonia, named coronavirus" exact="disease" post="2019 (COVID-19), is caused by a novel CoV, namely"/>
  <result pre="2019 (COVID-19), is caused by a novel CoV, namely severe" exact="acute" post="respiratory syndrome coronavirus 2 (SARS-CoV-2), previously known as 2019"/>
  <result pre="(COVID-19), is caused by a novel CoV, namely severe acute" exact="respiratory" post="syndrome coronavirus 2 (SARS-CoV-2), previously known as 2019 novel"/>
  <result pre="is caused by a novel CoV, namely severe acute respiratory" exact="syndrome" post="coronavirus 2 (SARS-CoV-2), previously known as 2019 novel coronavirus"/>
  <result pre="no vaccines against SARS-CoV-2 or specific therapeutic drugs for this" exact="communicable disease." post="Thus, a better understanding of SARS-CoV-2 is essential for"/>
  <result pre="subunit and transition of the S2 subunit into a highly" exact="stable" post="postfusion conformation [18]. In order to engage a host"/>
  <result pre="development of vaccines. Fig. 1 Structure and genome of severe" exact="acute" post="respiratory syndrome coronavirus 2 (SARS-CoV-2). (A) There are four"/>
  <result pre="of vaccines. Fig. 1 Structure and genome of severe acute" exact="respiratory" post="syndrome coronavirus 2 (SARS-CoV-2). (A) There are four structural"/>
  <result pre="vaccines. Fig. 1 Structure and genome of severe acute respiratory" exact="syndrome" post="coronavirus 2 (SARS-CoV-2). (A) There are four structural proteins"/>
  <result pre="and HCoV-HKU1) are able to cause a wide range of" exact="upper" post="respiratory tract infections (common cold), whereas SARS-CoV and MERS-CoV"/>
  <result pre="HCoV-HKU1) are able to cause a wide range of upper" exact="respiratory" post="tract infections (common cold), whereas SARS-CoV and MERS-CoV are"/>
  <result pre="able to cause a wide range of upper respiratory tract" exact="infections" post="(common cold), whereas SARS-CoV and MERS-CoV are responsible for"/>
  <result pre="infections (common cold), whereas SARS-CoV and MERS-CoV are responsible for" exact="atypical" post="pneumonia. The causes of different infection sites are likely"/>
  <result pre="MERS-CoV are responsible for atypical pneumonia. The causes of different" exact="infection" post="sites are likely related to the presence of dipeptidyl"/>
  <result pre="peptidase 4 (DPP4) and angiotensin-converting enzyme 2 (ACE2) in the" exact="lower" post="respiratory tract, which are the major human receptors for"/>
  <result pre="4 (DPP4) and angiotensin-converting enzyme 2 (ACE2) in the lower" exact="respiratory" post="tract, which are the major human receptors for the"/>
  <result pre="to spread from human to human. Upon entry into alveolar" exact="epithelial" post="cells, SARS-CoV-2 replicates rapidly and triggers a strong immune"/>
  <result pre="a strong immune response, resulting in cytokine storm syndromes and" exact="pulmonary" post="tissue damage. Cytokine storm syndromes, also known as hypercytokinaemia,"/>
  <result pre="as hypercytokinaemia, are a group of disorders characterised by the" exact="uncontrolled" post="production of pro-inflammatory cytokines and are important causes of"/>
  <result pre="uncontrolled production of pro-inflammatory cytokines and are important causes of" exact="acute respiratory distress syndrome" post="(ARDS) and multiple organ failure [27], [28], [29]. Analysis"/>
  <result pre="production of pro-inflammatory cytokines and are important causes of acute" exact="respiratory" post="distress syndrome (ARDS) and multiple organ failure [27], [28],"/>
  <result pre="pro-inflammatory cytokines and are important causes of acute respiratory distress" exact="syndrome" post="(ARDS) and multiple organ failure [27], [28], [29]. Analysis"/>
  <result pre="[29]. Analysis of the first 99 confirmed cases of SARS-CoV-2" exact="infection" post="revealed that cytokine storm syndromes occurred in patients with"/>
  <result pre="(17%) had ARDS, among whom 11 (11%) deteriorated within a" exact="short" post="period of time and died of multiple organ failure"/>
  <result pre="of multiple organ failure [30]. In addition, the numbers of" exact="total" post="T-cells, CD4+ T-cells and CD8+ T-cells are decreased in"/>
  <result pre="immune function in SARS-CoV-2-infected patients. ARDS, decreased immune function and" exact="secondary" post="infection further worsens respiratory failure. 4 Epidemiological characteristics of"/>
  <result pre="function in SARS-CoV-2-infected patients. ARDS, decreased immune function and secondary" exact="infection" post="further worsens respiratory failure. 4 Epidemiological characteristics of SARS-CoV-2"/>
  <result pre="patients. ARDS, decreased immune function and secondary infection further worsens" exact="respiratory" post="failure. 4 Epidemiological characteristics of SARS-CoV-2 4.1 Progress and"/>
  <result pre="the epidemic Since December 2019, multiple cases of patients with" exact="pneumonia" post="of unknown cause were successively reported from the Chinese"/>
  <result pre="exposure to the Huanan seafood market in Wuhan and the" exact="disease" post="was been confirmed to be an acute respiratory infection"/>
  <result pre="Wuhan and the disease was been confirmed to be an" exact="acute" post="respiratory infection caused by a novel CoV. To date,"/>
  <result pre="and the disease was been confirmed to be an acute" exact="respiratory" post="infection caused by a novel CoV. To date, the"/>
  <result pre="the disease was been confirmed to be an acute respiratory" exact="infection" post="caused by a novel CoV. To date, the number"/>
  <result pre="Commission of the People's Republic of China has recorded a" exact="total" post="of 80 304 confirmed cases of pneumonia with SARS-CoV-2"/>
  <result pre="has recorded a total of 80 304 confirmed cases of" exact="pneumonia" post="with SARS-CoV-2 infection from 34 provinces (districts and cities)."/>
  <result pre="total of 80 304 confirmed cases of pneumonia with SARS-CoV-2" exact="infection" post="from 34 provinces (districts and cities). These included 6806"/>
  <result pre="and 40 651 people were still undergoing medical observation. A" exact="total" post="of 137 confirmed cases were reported from Macao Special"/>
  <result pre="from Western Pacific Asia, Northern America, Eastern Mediterranean, Southeast Asia," exact="African" post="and Europe have reported confirmed cases of this disease,"/>
  <result pre="Europe have reported confirmed cases of this disease, making a" exact="total" post="tally of confirmed cases of 90 870 worldwide. 4.2"/>
  <result pre="to SARS-CoV-2 [36], suggesting that pangolin may be a potential" exact="intermediate" post="host for SARS-CoV-2. However, whether SARS-CoV-2 is transmitted directly"/>
  <result pre="whether SARS-CoV-2 is transmitted directly from bats or by an" exact="intermediate" post="host requires further confirmation. Learning from the role of"/>
  <result pre="SARS-CoV-2 The novel CoV can be transmitted between humans via" exact="respiratory" post="droplets. Notably, the respiratory tract is probably not the"/>
  <result pre="can be transmitted between humans via respiratory droplets. Notably, the" exact="respiratory" post="tract is probably not the only route of transmission."/>
  <result pre="A recent study showed that the enteric symptoms of COVID-19" exact="pneumonia" post="are associated with invaded ACE2-expressing enterocytes [42], suggesting that"/>
  <result pre="that the digestive tract is a potential route of SARS-CoV-2" exact="infection" post="besides the respiratory tract. However, additional studies are required"/>
  <result pre="tract is a potential route of SARS-CoV-2 infection besides the" exact="respiratory" post="tract. However, additional studies are required to test this"/>
  <result pre="possibility. In addition, whether transmission of SARS-CoV-2 can occur via" exact="breast" post="milk or vertically from mother to infant has not"/>
  <result pre="newborns infected with SARS-CoV-2 are also prone to develop severe" exact="pneumonia" post="[44,45]. Thus, these vulnerable patients should be considered as"/>
  <result pre="R0 can be implicitly defined as the average number of" exact="secondary" post="infections produced by an infectious person. It is generally"/>
  <result pre="can be implicitly defined as the average number of secondary" exact="infections" post="produced by an infectious person. It is generally believed"/>
  <result pre="as the average number of secondary infections produced by an" exact="infectious" post="person. It is generally believed that if R0 is"/>
  <result pre="and dyspnoea, with less common symptoms being nasal congestion, headache," exact="runny nose," post="sore throat, vomiting and diarrhoea. Severe patients often have"/>
  <result pre="nasal congestion, headache, runny nose, sore throat, vomiting and diarrhoea." exact="Severe" post="patients often have dyspnoea and/or hypoxemia 1 week after"/>
  <result pre="have dyspnoea and/or hypoxemia 1 week after onset, after which" exact="septic shock," post="ARDS, difficult-to-correct metabolic acidosis, and coagulation dysfunction develop rapidly."/>
  <result pre="1 week after onset, after which septic shock, ARDS, difficult-to-correct" exact="metabolic acidosis," post="and coagulation dysfunction develop rapidly. Of note, severe and"/>
  <result pre="mild patients show only low fever, mild fatigue and no" exact="pneumonia" post="[40,43]. These asymptomatic or mild cases can also spread"/>
  <result pre="of the first patient known to have died from SARS-CoV-2" exact="infection" post="[55]. Biopsy samples were obtained from lung tissue of"/>
  <result pre="infiltration was observed in lung tissue. Multinucleated giant cells with" exact="atypical" post="enlarged pneumocytes characterised by large nuclei, prominent nucleoli and"/>
  <result pre="amphophilic granular cytoplasm were observed in the intra-alveolar spaces, suggesting" exact="viral" post="cytopathic-like changes [55]. These pathological characteristics of COVID-19 are"/>
  <result pre="are highly similar to those seen in SARS-CoV and MERS-CoV" exact="infection" post="[56,57]. Taken together, understanding the pathological characteristics of this"/>
  <result pre="and unexplained fatigue. Typical CT presentations of COVID-19 patients include" exact="bilateral" post="pulmonary parenchymal ground-glass opacity, pulmonary consolidation and nodules, bilateral"/>
  <result pre="unexplained fatigue. Typical CT presentations of COVID-19 patients include bilateral" exact="pulmonary" post="parenchymal ground-glass opacity, pulmonary consolidation and nodules, bilateral diffuse"/>
  <result pre="presentations of COVID-19 patients include bilateral pulmonary parenchymal ground-glass opacity," exact="pulmonary" post="consolidation and nodules, bilateral diffuse distribution, sometimes with a"/>
  <result pre="include bilateral pulmonary parenchymal ground-glass opacity, pulmonary consolidation and nodules," exact="bilateral" post="diffuse distribution, sometimes with a rounded morphology, and a"/>
  <result pre="bilateral pulmonary parenchymal ground-glass opacity, pulmonary consolidation and nodules, bilateral" exact="diffuse" post="distribution, sometimes with a rounded morphology, and a peripheral"/>
  <result pre="bilateral diffuse distribution, sometimes with a rounded morphology, and a" exact="peripheral" post="lung distribution [58,59]. In the early course of disease,"/>
  <result pre="peripheral lung distribution [58,59]. In the early course of disease," exact="chest" post="images show multiple small patchy shadows and interstitial changes,"/>
  <result pre="and interstitial changes, which are evident in the lung periphery." exact="Severe" post="cases can spread to the bronchi with progress of"/>
  <result pre="gradually spread to the whole lung, and with infrequent interlobar" exact="pleural" post="thickening and pleural effusion. 4.10 Detection of SARS-CoV-2 Rapid"/>
  <result pre="the whole lung, and with infrequent interlobar pleural thickening and" exact="pleural" post="effusion. 4.10 Detection of SARS-CoV-2 Rapid and accurate detection"/>
  <result pre="molecular biological diagnosis technology based on nucleic acid sequences. The" exact="complete" post="SARS-CoV-2 genome sequences are available in GenBank. Thus, the"/>
  <result pre="acid of SARS-CoV-2 can be detected by RT-qPCR or by" exact="viral" post="gene sequencing of nasopharyngeal and oropharyngeal swabs, stool, sputum"/>
  <result pre="or oropharyngeal specimens may cause bleeding, especially in patients with" exact="thrombocytopenia" post="[32]. Importantly, To et al. found that SARS-CoV-2 could"/>
  <result pre="is a promising non-invasive specimen type for diagnosis, monitoring and" exact="infection" post="control of COVID-19 patients. Besides RT-qPCR, Zhang et al."/>
  <result pre="to the intensive care unit as soon as possible. 5.1" exact="General" post="treatments General treatment strategies include bed rest and supportive"/>
  <result pre="intensive care unit as soon as possible. 5.1 General treatments" exact="General" post="treatment strategies include bed rest and supportive treatments, ensuring"/>
  <result pre="monitoring vital signs (heart rate, pulse, blood pressure, oxygen saturation," exact="respiratory" post="rate, etc.). 5.2 Antiviral therapy 5.2.1 Interferon-alpha (IFNα) IFNα"/>
  <result pre="Interferon-alpha (IFNα) IFNα is a member of the family of" exact="type I" post="IFNs that plays an important role in host resistance"/>
  <result pre="IFNs that plays an important role in host resistance to" exact="viral infection." post="IFNα suppresses viral infection by directly interfering with replication"/>
  <result pre="important role in host resistance to viral infection. IFNα suppresses" exact="viral infection" post="by directly interfering with replication of the virus and"/>
  <result pre="role in host resistance to viral infection. IFNα suppresses viral" exact="infection" post="by directly interfering with replication of the virus and"/>
  <result pre="has also been reported that cynomolgus monkeys are protected from" exact="infection" post="with SARS CoV by treatment with IFNα [66]. Moreover,"/>
  <result pre="inhibitor that interferes with the replication and synthesis of human" exact="immunodeficiency" post="virus (HIV), leading to the production of immature, non-infectious"/>
  <result pre="patients. 5.2.4 Chloroquine Chloroquine is a widely used antimalarial and" exact="autoimmune" post="disease drug. Recently, chloroquine has been reported as a"/>
  <result pre="5.2.4 Chloroquine Chloroquine is a widely used antimalarial and autoimmune" exact="disease" post="drug. Recently, chloroquine has been reported as a potential"/>
  <result pre="5.2.5 Arbidol (umifenovir) Arbidol is an antiviral drug against influenza" exact="infection" post="that is widely used in Russia and China. Arbidol"/>
  <result pre="antiviral drugs produced certain benefits in the treatment of COVID-19" exact="pneumonia" post="[81], [82], [83]. Currently, many randomised clinical controlled trials"/>
  <result pre="being carried out studying the efficacy of Arbidol on COVID-19" exact="pneumonia" post="in China. 5.2.6 Remdesivir The nucleoside analogue remdesivir (GS-5734)"/>
  <result pre="an in vitro study showed that remdesivir potently blocked SARS-CoV-2" exact="infection" post="at low-micromolar concentrations and showed a high selectivity index"/>
  <result pre="selectivity index [79]. In addition, the first case of SARS-CoV-2" exact="infection" post="in the USA was treated with intravenous remdesivir when"/>
  <result pre="important immune cells necessary for defence against microbe-infected, stressed or" exact="malignant" post="cells. Human NK cells lyse antibody-coated virus-infected cells via"/>
  <result pre="cells can exert antiviral activity by mediating ADCC against SARS-CoV," exact="herpes" post="simplex virus type 1 (HSV-1), cytomegalovirus and HIV [87],"/>
  <result pre="antiviral activity by mediating ADCC against SARS-CoV, herpes simplex virus" exact="type 1" post="(HSV-1), cytomegalovirus and HIV [87], [88], [89]. Umbilical cord"/>
  <result pre="virus type 1 (HSV-1), cytomegalovirus and HIV [87], [88], [89]." exact="Umbilical" post="cord blood is a promising source of allogeneic NK"/>
  <result pre="cell therapy, to the treatment of the newly emerged SARS-CoV-2" exact="infection" post="[90]. Whilst developing new drugs, new vaccines or clinical"/>
  <result pre="strategy for the treatment and prevention of COVID-19 pneumonia. 5.3.2" exact="Mesenchymal" post="stem cells (MSCs) It is well known that MSCs"/>
  <result pre="well known that MSCs have strong anti-inflammatory and immunomodulatory functions." exact="Umbilical" post="cord blood and placenta are good sources of MSCs."/>
  <result pre="and ARDS by suppressing the infiltration of immune cells to" exact="pulmonary" post="tissues and pro-inflammatory cytokine secretion [91], [92], [93], [94]."/>
  <result pre="[91], [92], [93], [94]. In addition, MSCs contribute to reducing" exact="lung fibrosis" post="and enhancing tissue repair [95,96]. Besides routine antiviral treatment,"/>
  <result pre="it is important to treat cytokine storm syndromes, ARDS and" exact="acute" post="lung injury in patients with severe COVID-19 to prevent"/>
  <result pre="in patients with severe COVID-19 to prevent progression of the" exact="disease" post="and to reduce mortality. Thus, MSCs may be a"/>
  <result pre="convalescent plasma from recovered patients can effectively treat patients with" exact="viral" post="infections. Convalescent plasma therapy has been widely used in"/>
  <result pre="viral infections. Convalescent plasma therapy has been widely used in" exact="infectious diseases" post="such as poliomyelitis, influenza A (H5N1) and Ebola [97],"/>
  <result pre="treatment with convalescent plasma during the early course of the" exact="disease" post="with certain clinical benefits, including a reduction of plasma"/>
  <result pre="disease with certain clinical benefits, including a reduction of plasma" exact="viral" post="load from ~105 copies/mL to undetectable levels 24 h"/>
  <result pre="to have the potential to inhibit ACE2 and therefore block" exact="infection" post="with SARS-CoV-2 [112]. Baicalin, another traditional Chinese herbal medicine,"/>
  <result pre="that SARS-CoV-2 enters lung cells by binding to ACE2. Besides" exact="pulmonary" post="tissue, ACE2 is also highly expressed in other tissues"/>
  <result pre="health caused by SARS-CoV-2, effective prevention and treatment of COVID-19" exact="pneumonia" post="will be urgently needed. However, the development of drugs"/>
  <result pre="it is necessary to make full use of the currently" exact="limited" post="evidence for therapeutic drugs to develop strategies of drug"/>
  <result pre="A number of antiviral drugs and treatment methods for SARS-CoV" exact="infection" post="have also been considered for the treatment and prevention"/>
  <result pre="of animal models that recapitulate the various aspects of human" exact="disease" post="and determinants of vaccine safety and efficacy. References References"/>
  <result pre="SARS: strategies for controlling emerging coronavirusesNat Rev Microbiol11201383684810.1038/nrmicro314324217413 5ZumlaAHuiDSPerlmanSMiddle East" exact="respiratory" post="syndromeLancet3862015995100710.1016/S0140-6736(15)60454-826049252 6HuiDSAzharEIKimYJMemishZAOhMDZumlaAMiddle East respiratory syndrome coronavirus: risk factors and"/>
  <result pre="emerging coronavirusesNat Rev Microbiol11201383684810.1038/nrmicro314324217413 5ZumlaAHuiDSPerlmanSMiddle East respiratory syndromeLancet3862015995100710.1016/S0140-6736(15)60454-826049252 6HuiDSAzharEIKimYJMemishZAOhMDZumlaAMiddle East" exact="respiratory" post="syndrome coronavirus: risk factors and determinants of primary, household,"/>
  <result pre="coronavirusesNat Rev Microbiol11201383684810.1038/nrmicro314324217413 5ZumlaAHuiDSPerlmanSMiddle East respiratory syndromeLancet3862015995100710.1016/S0140-6736(15)60454-826049252 6HuiDSAzharEIKimYJMemishZAOhMDZumlaAMiddle East respiratory" exact="syndrome" post="coronavirus: risk factors and determinants of primary, household, and"/>
  <result pre="South Korea and China: a potential outbreak threat?Lancet38520152349235010.1016/S0140-6736(15)60859-526088634 8ReuskenCBHaagmansBLMüllerMAGutierrezCGodekeGJMeyerBMiddle East" exact="respiratory" post="syndrome coronavirus neutralising serum antibodies in dromedary camels: a"/>
  <result pre="Korea and China: a potential outbreak threat?Lancet38520152349235010.1016/S0140-6736(15)60859-526088634 8ReuskenCBHaagmansBLMüllerMAGutierrezCGodekeGJMeyerBMiddle East respiratory" exact="syndrome" post="coronavirus neutralising serum antibodies in dromedary camels: a comparative"/>
  <result pre="the 2019 novel human-pathogenic coronavirus isolated from a patient with" exact="atypical" post="pneumonia after visiting WuhanEmerg Microbes Infect9202022123610.1080/22221751.2020.171990231987001 16WuAPengYHuangBDingXWangXNiuPGenome composition and"/>
  <result pre="2019 novel human-pathogenic coronavirus isolated from a patient with atypical" exact="pneumonia" post="after visiting WuhanEmerg Microbes Infect9202022123610.1080/22221751.2020.171990231987001 16WuAPengYHuangBDingXWangXNiuPGenome composition and divergence"/>
  <result pre="novel coronavirus outbreak in Wuhan, ChinaInt J Infect Dis91202026426610.1016/j.ijid.2020.01.00931953166 26ZhouPYangXLWangXGHuBZhangLZhangWA" exact="pneumonia" post="outbreak associated with a new coronavirus of probable bat"/>
  <result pre="30ChenNZhouMDongXQuJGongFHanYEpidemiological and clinical characteristics of 99 cases of 2019 novel" exact="coronavirus pneumonia" post="in Wuhan, China: a descriptive studyLancet395202050751310.1016/S0140-6736(20)30211-732007143 31DiaoBWangCTanYChenXLiuYNingLReduction and functional"/>
  <result pre="and clinical characteristics of 99 cases of 2019 novel coronavirus" exact="pneumonia" post="in Wuhan, China: a descriptive studyLancet395202050751310.1016/S0140-6736(20)30211-732007143 31DiaoBWangCTanYChenXLiuYNingLReduction and functional"/>
  <result pre="31DiaoBWangCTanYChenXLiuYNingLReduction and functional exhaustion of T cells in patients with" exact="coronavirus disease" post="2019 (COVID-19)medRxiv2020 Feb 2010.1101/2020.02.18.20024364 32ChanJFYuanSKokKHToKKChuHYangJA familial cluster of pneumonia"/>
  <result pre="and functional exhaustion of T cells in patients with coronavirus" exact="disease" post="2019 (COVID-19)medRxiv2020 Feb 2010.1101/2020.02.18.20024364 32ChanJFYuanSKokKHToKKChuHYangJA familial cluster of pneumonia"/>
  <result pre="in patients with coronavirus disease 2019 (COVID-19)medRxiv2020 Feb 2010.1101/2020.02.18.20024364 32ChanJFYuanSKokKHToKKChuHYangJA" exact="familial" post="cluster of pneumonia associated with the 2019 novel coronavirus"/>
  <result pre="coronavirus disease 2019 (COVID-19)medRxiv2020 Feb 2010.1101/2020.02.18.20024364 32ChanJFYuanSKokKHToKKChuHYangJA familial cluster of" exact="pneumonia" post="associated with the 2019 novel coronavirus indicating person-to-person transmission:"/>
  <result pre="origins and receptor bindingLancet395202056557410.1016/S0140-6736(20)30251-832007145 35ZhuNZhangDWangWLiXYangBSongJA novel coronavirus from patients with" exact="pneumonia" post="in China, 2019N Engl J Med382202072773310.1056/NEJMoa200101731978945 36LamTT-YShumMH-HZhuH-CTongY-GNiX-BLiaoY-SIdentifying SARS-CoV-2 related"/>
  <result pre="SARS-CoV-2 related coronaviruses in Malayan pangolinsnature202010.1038/s41586-020-2169-0 37LuCWLiuXFJiaZF2019-nCoV transmission through the" exact="ocular" post="surface must not be ignoredLancet3952020e3910.1016/S0140-6736(20)30313-532035510 38CarlosWGDela CruzCSCaoBPasnickSJamilSNovel Wuhan (2019-nCoV)"/>
  <result pre="40WangDHuBHuCZhuFLiuXZhangJClinical characteristics of 138 hospitalized patients with 2019 novel coronavirus-infected" exact="pneumonia" post="in Wuhan, ChinaJAMA2020 Feb 710.1001/jama.2020.1585[Epub ahead of print] 41HolshueMLDeBoltCLindquistSLofyKHWiesmanJBruceHFirst"/>
  <result pre="ChinaLancet395202049750610.1016/S0140-6736(20)30183-531986264 44ChenHGuoJWangCLuoFYuXZhangWClinical characteristics and intrauterine vertical transmission potential of COVID-19" exact="infection" post="in nine pregnant women: a retrospective review of medical"/>
  <result pre="recordsLancet395202080981510.1016/S0140-6736(20)30360-332151335 45collab: Working Group for the Prevention and Control of" exact="Neonatal" post="2019-nCoV Infection in the Perinatal Period of the Editorial"/>
  <result pre="Working Group for the Prevention and Control of Neonatal 2019-nCoV" exact="Infection" post="in the Perinatal Period of the Editorial Committee of"/>
  <result pre="the Editorial Committee of Chinese Journal of Contemporary PediatricsPerinatal and" exact="neonatal" post="management plan for prevention and control of 2019 novel"/>
  <result pre="neonatal management plan for prevention and control of 2019 novel" exact="coronavirus infection" post="(1st Edition) [in Chinese]Zhongguo Dang Dai Er Ke Za"/>
  <result pre="management plan for prevention and control of 2019 novel coronavirus" exact="infection" post="(1st Edition) [in Chinese]Zhongguo Dang Dai Er Ke Za"/>
  <result pre="Ke Za Zhi222020879032051071 46BackerJAKlinkenbergDWallingaJIncubation period of 2019 novel coronavirus (2019-nCoV)" exact="infections" post="among travellers from Wuhan, China, 20–28 January 2020Euro Surveill25202010.2807/1560-7917.ES.2020.25.5.2000062"/>
  <result pre="China, 20–28 January 2020Euro Surveill25202010.2807/1560-7917.ES.2020.25.5.2000062 47LauerSAGrantzKHBiQJonesFKZhengQMeredithHThe Incubation Period of Coronavirus" exact="Disease" post="2019 (COVID-19) From Publicly Reported Confirmed Cases: Estimation and"/>
  <result pre="Confirmed Cases: Estimation and Application.Ann Intern Med202010.7326/M20-0504 48LesslerJReichNGBrookmeyerRPerlTMNelsonKECummingsDAIncubation periods of" exact="acute" post="respiratory viral infections: a systematic reviewLancet Infect Dis9200929130010.1016/S1473-3099(09)70069-619393959 49VariaMWilsonSSarwalSMcGeerAGournisEGalanisEInvestigation"/>
  <result pre="Cases: Estimation and Application.Ann Intern Med202010.7326/M20-0504 48LesslerJReichNGBrookmeyerRPerlTMNelsonKECummingsDAIncubation periods of acute" exact="respiratory" post="viral infections: a systematic reviewLancet Infect Dis9200929130010.1016/S1473-3099(09)70069-619393959 49VariaMWilsonSSarwalSMcGeerAGournisEGalanisEInvestigation of"/>
  <result pre="Estimation and Application.Ann Intern Med202010.7326/M20-0504 48LesslerJReichNGBrookmeyerRPerlTMNelsonKECummingsDAIncubation periods of acute respiratory" exact="viral" post="infections: a systematic reviewLancet Infect Dis9200929130010.1016/S1473-3099(09)70069-619393959 49VariaMWilsonSSarwalSMcGeerAGournisEGalanisEInvestigation of a"/>
  <result pre="reviewLancet Infect Dis9200929130010.1016/S1473-3099(09)70069-619393959 49VariaMWilsonSSarwalSMcGeerAGournisEGalanisEInvestigation of a nosocomial outbreak of severe" exact="acute" post="respiratory syndrome (SARS) in Toronto, CanadaCMAJ169200328529212925421 50AssiriAAl-TawfiqJAAl-RabeeahAAAl-RabiahFAAl-HajjarSAl-BarrakAEpidemiological, demographic, and"/>
  <result pre="Infect Dis9200929130010.1016/S1473-3099(09)70069-619393959 49VariaMWilsonSSarwalSMcGeerAGournisEGalanisEInvestigation of a nosocomial outbreak of severe acute" exact="respiratory" post="syndrome (SARS) in Toronto, CanadaCMAJ169200328529212925421 50AssiriAAl-TawfiqJAAl-RabeeahAAAl-RabiahFAAl-HajjarSAl-BarrakAEpidemiological, demographic, and clinical"/>
  <result pre="Dis9200929130010.1016/S1473-3099(09)70069-619393959 49VariaMWilsonSSarwalSMcGeerAGournisEGalanisEInvestigation of a nosocomial outbreak of severe acute respiratory" exact="syndrome" post="(SARS) in Toronto, CanadaCMAJ169200328529212925421 50AssiriAAl-TawfiqJAAl-RabeeahAAAl-RabiahFAAl-HajjarSAl-BarrakAEpidemiological, demographic, and clinical characteristics"/>
  <result pre="demographic, and clinical characteristics of 47 cases of Middle East" exact="respiratory" post="syndrome coronavirus disease from Saudi Arabia: a descriptive studyLancet"/>
  <result pre="and clinical characteristics of 47 cases of Middle East respiratory" exact="syndrome" post="coronavirus disease from Saudi Arabia: a descriptive studyLancet Infect"/>
  <result pre="clinical characteristics of 47 cases of Middle East respiratory syndrome" exact="coronavirus disease" post="from Saudi Arabia: a descriptive studyLancet Infect Dis13201375276110.1016/S1473-3099(13)70204-423891402 51RotheCSchunkMSothmannPBretzelGFroeschlGWallrauchCTransmission"/>
  <result pre="characteristics of 47 cases of Middle East respiratory syndrome coronavirus" exact="disease" post="from Saudi Arabia: a descriptive studyLancet Infect Dis13201375276110.1016/S1473-3099(13)70204-423891402 51RotheCSchunkMSothmannPBretzelGFroeschlGWallrauchCTransmission"/>
  <result pre="Saudi Arabia: a descriptive studyLancet Infect Dis13201375276110.1016/S1473-3099(13)70204-423891402 51RotheCSchunkMSothmannPBretzelGFroeschlGWallrauchCTransmission of 2019-nCoV" exact="infection" post="from an asymptomatic contact in GermanyN Engl J Med382202097097110.1056/NEJMc200146832003551"/>
  <result pre="novel coronavirus (2019-nCoV)Euro Surveill25202010.2807/1560-7917.ES.2020.25.5.2000080 53LipsitchMCohenTCooperBRobinsJMMaSJamesLTransmission dynamics and control of severe" exact="acute" post="respiratory syndromeScience30020031966197010.1126/science.108661612766207 54LiuYGayleAAWilder-SmithARocklövJThe reproductive number of COVID-19 is higher"/>
  <result pre="coronavirus (2019-nCoV)Euro Surveill25202010.2807/1560-7917.ES.2020.25.5.2000080 53LipsitchMCohenTCooperBRobinsJMMaSJamesLTransmission dynamics and control of severe acute" exact="respiratory" post="syndromeScience30020031966197010.1126/science.108661612766207 54LiuYGayleAAWilder-SmithARocklövJThe reproductive number of COVID-19 is higher compared"/>
  <result pre="coronavirusJ Travel Med27202010.1093/jtm/taaa021pii: taaa021 55XuZShiLWangYZhangJHuangLZhangCPathological findings of COVID-19 associated with" exact="acute" post="respiratory distress syndromeLancet Respir Med2020 Feb 1810.1016/S2213-2600(20)30076-X[Epub ahead of"/>
  <result pre="Travel Med27202010.1093/jtm/taaa021pii: taaa021 55XuZShiLWangYZhangJHuangLZhangCPathological findings of COVID-19 associated with acute" exact="respiratory" post="distress syndromeLancet Respir Med2020 Feb 1810.1016/S2213-2600(20)30076-X[Epub ahead of print]"/>
  <result pre="Feb 1810.1016/S2213-2600(20)30076-X[Epub ahead of print] 56DingYWangHShenHLiZGengJHanHThe clinical pathology of severe" exact="acute" post="respiratory syndrome (SARS): a report from ChinaJ Pathol200200328228910.1002/path.144012845623 57NgDLAl"/>
  <result pre="1810.1016/S2213-2600(20)30076-X[Epub ahead of print] 56DingYWangHShenHLiZGengJHanHThe clinical pathology of severe acute" exact="respiratory" post="syndrome (SARS): a report from ChinaJ Pathol200200328228910.1002/path.144012845623 57NgDLAl HosaniFKeatingMKGerberSIJonesTLMetcalfeMGClinicopathologic,"/>
  <result pre="ahead of print] 56DingYWangHShenHLiZGengJHanHThe clinical pathology of severe acute respiratory" exact="syndrome" post="(SARS): a report from ChinaJ Pathol200200328228910.1002/path.144012845623 57NgDLAl HosaniFKeatingMKGerberSIJonesTLMetcalfeMGClinicopathologic, immunohistochemical,"/>
  <result pre="and ultrastructural findings of a fatal case of Middle East" exact="respiratory" post="syndrome coronavirus infection in the United Arab Emirates, April"/>
  <result pre="ultrastructural findings of a fatal case of Middle East respiratory" exact="syndrome" post="coronavirus infection in the United Arab Emirates, April 2014Am"/>
  <result pre="findings of a fatal case of Middle East respiratory syndrome" exact="coronavirus infection" post="in the United Arab Emirates, April 2014Am J Pathol186201665265810.1016/j.ajpath.2015.10.02426857507"/>
  <result pre="of a fatal case of Middle East respiratory syndrome coronavirus" exact="infection" post="in the United Arab Emirates, April 2014Am J Pathol186201665265810.1016/j.ajpath.2015.10.02426857507"/>
  <result pre="manifestations in a patient recovered from 2019 novel coronavirus (2019-nCoV)" exact="pneumonia" post="in Wuhan, ChinaRadiology29520202010.1148/radiol.202020026932032497 60CormanVMLandtOKaiserMMolenkampRMeijerAChuDKWDetection of 2019 novel coronavirus (2019-nCoV)"/>
  <result pre="of COVID-19 using CRISPR diagnostics. https://broad.io/sherlockprotocol[accessed 1 April 2020]. 64StröherUDiCaroALiYStrongJEAokiFPlummerFSevere" exact="acute" post="respiratory syndrome-related coronavirus is inhibited by interferon-alphaJ Infect Dis18920041164116710.1086/38259715031783"/>
  <result pre="COVID-19 using CRISPR diagnostics. https://broad.io/sherlockprotocol[accessed 1 April 2020]. 64StröherUDiCaroALiYStrongJEAokiFPlummerFSevere acute" exact="respiratory" post="syndrome-related coronavirus is inhibited by interferon-alphaJ Infect Dis18920041164116710.1086/38259715031783 65ZorzittoJGalliganCLUengJJFishENCharacterization"/>
  <result pre="65ZorzittoJGalliganCLUengJJFishENCharacterization of the antiviral effects of interferon-α against a SARS-like" exact="coronavirus infection" post="in vitroCell Res16200622022910.1038/sj.cr.731003016474437 66HaagmansBLKuikenTMartinaBEFouchierRARimmelzwaanGFvan AmerongenGPegylated interferon-α protects type 1"/>
  <result pre="of the antiviral effects of interferon-α against a SARS-like coronavirus" exact="infection" post="in vitroCell Res16200622022910.1038/sj.cr.731003016474437 66HaagmansBLKuikenTMartinaBEFouchierRARimmelzwaanGFvan AmerongenGPegylated interferon-α protects type 1"/>
  <result pre="SARS-like coronavirus infection in vitroCell Res16200622022910.1038/sj.cr.731003016474437 66HaagmansBLKuikenTMartinaBEFouchierRARimmelzwaanGFvan AmerongenGPegylated interferon-α protects" exact="type 1" post="pneumocytes against SARS coronavirus infection in macaquesNat Med10200429029310.1038/nm100114981511 67LoutfyMRBlattLMSiminovitchKAWardSWolffBLhoHInterferon"/>
  <result pre="Res16200622022910.1038/sj.cr.731003016474437 66HaagmansBLKuikenTMartinaBEFouchierRARimmelzwaanGFvan AmerongenGPegylated interferon-α protects type 1 pneumocytes against SARS" exact="coronavirus infection" post="in macaquesNat Med10200429029310.1038/nm100114981511 67LoutfyMRBlattLMSiminovitchKAWardSWolffBLhoHInterferon alfacon-1 plus corticosteroids in severe"/>
  <result pre="66HaagmansBLKuikenTMartinaBEFouchierRARimmelzwaanGFvan AmerongenGPegylated interferon-α protects type 1 pneumocytes against SARS coronavirus" exact="infection" post="in macaquesNat Med10200429029310.1038/nm100114981511 67LoutfyMRBlattLMSiminovitchKAWardSWolffBLhoHInterferon alfacon-1 plus corticosteroids in severe"/>
  <result pre="infection in macaquesNat Med10200429029310.1038/nm100114981511 67LoutfyMRBlattLMSiminovitchKAWardSWolffBLhoHInterferon alfacon-1 plus corticosteroids in severe" exact="acute" post="respiratory syndrome: a preliminary studyJAMA29020033222322810.1001/jama.290.24.322214693875 68WalmsleySBernsteinBKingMArribasJBeallGRuanePLopinavir–ritonavir versus nelfinavir for"/>
  <result pre="in macaquesNat Med10200429029310.1038/nm100114981511 67LoutfyMRBlattLMSiminovitchKAWardSWolffBLhoHInterferon alfacon-1 plus corticosteroids in severe acute" exact="respiratory" post="syndrome: a preliminary studyJAMA29020033222322810.1001/jama.290.24.322214693875 68WalmsleySBernsteinBKingMArribasJBeallGRuanePLopinavir–ritonavir versus nelfinavir for the"/>
  <result pre="of the binding abilities of ritonavir and lopinavir to Wuhan" exact="pneumonia" post="coronavirus proteasesbioRxiv2020 Feb 310.1101/2020.01.31.929695 71ChuCMChengVCHungIFWongMMChanKHChanKSRole of lopinavir/ritonavir in the"/>
  <result pre="disturbances of in vitro cytokine production in patients with severe" exact="acute" post="respiratory syndrome (SARS) treated with ribavirin and steroidsClin Exp"/>
  <result pre="of in vitro cytokine production in patients with severe acute" exact="respiratory" post="syndrome (SARS) treated with ribavirin and steroidsClin Exp Immunol135200446747310.1111/j.1365-2249.2003.02391.x15008980"/>
  <result pre="in vitro cytokine production in patients with severe acute respiratory" exact="syndrome" post="(SARS) treated with ribavirin and steroidsClin Exp Immunol135200446747310.1111/j.1365-2249.2003.02391.x15008980 76PeirisJSLaiSTPoonLLGuanYYamLYLimWCoronavirus"/>
  <result pre="steroidsClin Exp Immunol135200446747310.1111/j.1365-2249.2003.02391.x15008980 76PeirisJSLaiSTPoonLLGuanYYamLYLimWCoronavirus as a possible cause of severe" exact="acute" post="respiratory syndromeLancet36120031319132510.1016/s0140-6736(03)13077-212711465 77SavarinoADi TraniLDonatelliICaudaRCassoneANew insights into the antiviral effects"/>
  <result pre="Exp Immunol135200446747310.1111/j.1365-2249.2003.02391.x15008980 76PeirisJSLaiSTPoonLLGuanYYamLYLimWCoronavirus as a possible cause of severe acute" exact="respiratory" post="syndromeLancet36120031319132510.1016/s0140-6736(03)13077-212711465 77SavarinoADi TraniLDonatelliICaudaRCassoneANew insights into the antiviral effects of"/>
  <result pre="Infect Dis62006676910.1016/S1473-3099(06)70361-916439323 78YanYZouZSunYLiXXuKFWeiYAnti-malaria drug chloroquine is highly effective in treating" exact="avian influenza" post="A H5N1 virus infection in an animal modelCell Res23201330030210.1038/cr.2012.16523208422"/>
  <result pre="chloroquine is highly effective in treating avian influenza A H5N1" exact="virus infection" post="in an animal modelCell Res23201330030210.1038/cr.2012.16523208422 79WangMCaoRZhangLYangXLiuJXuMRemdesivir and chloroquine effectively"/>
  <result pre="is highly effective in treating avian influenza A H5N1 virus" exact="infection" post="in an animal modelCell Res23201330030210.1038/cr.2012.16523208422 79WangMCaoRZhangLYangXLiuJXuMRemdesivir and chloroquine effectively"/>
  <result pre="of arbidol and its derivatives against the pathogen of severe" exact="acute" post="respiratory syndrome in the cell cultures [in Russian]Vopr Virusol532008913"/>
  <result pre="arbidol and its derivatives against the pathogen of severe acute" exact="respiratory" post="syndrome in the cell cultures [in Russian]Vopr Virusol532008913 81WangZChenXLuYChenFZhangWClinical"/>
  <result pre="and its derivatives against the pathogen of severe acute respiratory" exact="syndrome" post="in the cell cultures [in Russian]Vopr Virusol532008913 81WangZChenXLuYChenFZhangWClinical characteristics"/>
  <result pre="characteristics and therapeutic procedure for four cases with 2019 novel" exact="coronavirus pneumonia" post="receiving combined Chinese and Western medicine treatmentBiosci Trends142020646810.5582/bst.2020.0103032037389 82ZhangJZhouLYangYPengWWangWChenXTherapeutic"/>
  <result pre="and therapeutic procedure for four cases with 2019 novel coronavirus" exact="pneumonia" post="receiving combined Chinese and Western medicine treatmentBiosci Trends142020646810.5582/bst.2020.0103032037389 82ZhangJZhouLYangYPengWWangWChenXTherapeutic"/>
  <result pre="medicine treatmentBiosci Trends142020646810.5582/bst.2020.0103032037389 82ZhangJZhouLYangYPengWWangWChenXTherapeutic and triage strategies for 2019 novel" exact="coronavirus disease" post="in fever clinicsLancet Respir Med82020e11e1210.1016/S2213-2600(20)30071-032061335 83XuX-WWuX-XJiangX-GXuKJYingLJMaCLClinical findings in a"/>
  <result pre="treatmentBiosci Trends142020646810.5582/bst.2020.0103032037389 82ZhangJZhouLYangYPengWWangWChenXTherapeutic and triage strategies for 2019 novel coronavirus" exact="disease" post="in fever clinicsLancet Respir Med82020e11e1210.1016/S2213-2600(20)30071-032061335 83XuX-WWuX-XJiangX-GXuKJYingLJMaCLClinical findings in a"/>
  <result pre="of MERS-CoV infectionProc Natl Acad Sci U S A11720206771677610.1073/pnas.192208311732054787 85AgostiniMLAndresELSimsACGrahamRLSheahanTPLuXCoronavirus" exact="susceptibility to" post="the antiviral remdesivir (GS-5734) is mediated by the viral"/>
  <result pre="susceptibility to the antiviral remdesivir (GS-5734) is mediated by the" exact="viral" post="polymerase and the proofreading exoribonucleasemBio9201810.1128/mBio.00221-18pii: e00221-18 86HammerQRuckertTRomagnaniCNatural killer cell"/>
  <result pre="and the proofreading exoribonucleasemBio9201810.1128/mBio.00221-18pii: e00221-18 86HammerQRuckertTRomagnaniCNatural killer cell specificity for" exact="viral" post="infectionsNat Immunol19201880080810.1038/s41590-018-0163-630026479 87DaiHSCaligiuriMA.Molecular basis for the recognition of herpes"/>
  <result pre="for viral infectionsNat Immunol19201880080810.1038/s41590-018-0163-630026479 87DaiHSCaligiuriMA.Molecular basis for the recognition of" exact="herpes" post="simplex virus type 1 infection by human natural killer"/>
  <result pre="Immunol19201880080810.1038/s41590-018-0163-630026479 87DaiHSCaligiuriMA.Molecular basis for the recognition of herpes simplex virus" exact="type 1" post="infection by human natural killer cellsFront Immunol9201818310.3389/fimmu.2018.0018329483911 88AraseHMocarskiESCampbellAEHillABLanierLLDirect recognition"/>
  <result pre="basis for the recognition of herpes simplex virus type 1" exact="infection" post="by human natural killer cellsFront Immunol9201818310.3389/fimmu.2018.0018329483911 88AraseHMocarskiESCampbellAEHillABLanierLLDirect recognition of"/>
  <result pre="involvement of natural killer cells in the pathogenesis of severe" exact="acute" post="respiratory syndromeAm J Clin Pathol121200450751110.1309/WPK7-Y2XK-NF4C-BF3R15080302 90Sorrento and Celularity to"/>
  <result pre="of natural killer cells in the pathogenesis of severe acute" exact="respiratory" post="syndromeAm J Clin Pathol121200450751110.1309/WPK7-Y2XK-NF4C-BF3R15080302 90Sorrento and Celularity to initiate"/>
  <result pre="initiate emergency allogeneic natural killer (NK) cell therapy development for" exact="coronavirus infection." post="https://seekingalpha.com/pr/17762358-sorrento-and-celularity-to-initiate-emergency-allogeneic-natural-killer-nk-cell-therapy[accessed 1 April 2020]. 91OrtizLADutreilMFattmanCPandeyACTorresGGoKInterleukin 1 receptor antagonist mediates"/>
  <result pre="bone marrow-derived mesenchymal stem cells improves survival and attenuates endotoxin-induced" exact="acute" post="lung injury in miceJ Immunol17920071855186310.4049/jimmunol.179.3.185517641052 93MoodleyYAtienzaDManuelpillaiUSamuelCSTchongueJIlancheranSHuman umbilical cord mesenchymal"/>
  <result pre="of bleomycin-induced lung injuryAm J Pathol175200930331310.2353/ajpath.2009.08062919497992 94MatthayMAGoolaertsAHowardJPLeeJWMesenchymal stem cells for" exact="acute" post="lung injury: preclinical evidenceCrit Care Med3810 Suppl2010S569S57310.1097/CCM.0b013e3181f1ff1d21164399 95KumamotoMNishiwakiTMatsuoNKimuraHMatsushimaKMinimally cultured"/>
  <result pre="Med35720071450145110.1056/NEJMc07035917914053 98van GriensvenJEdwardsTde LamballerieXSempleMGGallianPBaizeSEvaluation of convalescent plasma for Ebola virus" exact="disease" post="in GuineaN Engl J Med3742016334210.1056/NEJMoa151181226735992 99RinaldoCRJr.Passive immunization against poliomyelitis:"/>
  <result pre="Hong KongEur J Clin Microbiol Infect Dis242005444610.1007/s10096-004-1271-915616839 101WongSSYuenKY.The management of" exact="coronavirus infections" post="with particular reference to SARSJ Antimicrob Chemother62200843744110.1093/jac/dkn24318565970 102YehKMChiuehTSSiuLKLinJCChanPKPengMYExperience of"/>
  <result pre="KongEur J Clin Microbiol Infect Dis242005444610.1007/s10096-004-1271-915616839 101WongSSYuenKY.The management of coronavirus" exact="infections" post="with particular reference to SARSJ Antimicrob Chemother62200843744110.1093/jac/dkn24318565970 102YehKMChiuehTSSiuLKLinJCChanPKPengMYExperience of"/>
  <result pre="SARSJ Antimicrob Chemother62200843744110.1093/jac/dkn24318565970 102YehKMChiuehTSSiuLKLinJCChanPKPengMYExperience of using convalescent plasma for severe" exact="acute" post="respiratory syndrome among healthcare workers in a Taiwan hospitalJ"/>
  <result pre="Antimicrob Chemother62200843744110.1093/jac/dkn24318565970 102YehKMChiuehTSSiuLKLinJCChanPKPengMYExperience of using convalescent plasma for severe acute" exact="respiratory" post="syndrome among healthcare workers in a Taiwan hospitalJ Antimicrob"/>
  <result pre="Chemother62200843744110.1093/jac/dkn24318565970 102YehKMChiuehTSSiuLKLinJCChanPKPengMYExperience of using convalescent plasma for severe acute respiratory" exact="syndrome" post="among healthcare workers in a Taiwan hospitalJ Antimicrob Chemother56200591992210.1093/jac/dki34616183666"/>
  <result pre="103ter MeulenJBakkerABvan den BrinkENWeverlingGJMartinaBEHaagmansBLHuman monoclonal antibody as prophylaxis for SARS" exact="coronavirus infection" post="in ferretsLancet36320042139214110.1016/S0140-6736(04)16506-915220038 104ter MeulenJvan den BrinkENPoonLLMarissenWELeungCSCoxFHuman monoclonal antibody combination"/>
  <result pre="MeulenJBakkerABvan den BrinkENWeverlingGJMartinaBEHaagmansBLHuman monoclonal antibody as prophylaxis for SARS coronavirus" exact="infection" post="in ferretsLancet36320042139214110.1016/S0140-6736(04)16506-915220038 104ter MeulenJvan den BrinkENPoonLLMarissenWELeungCSCoxFHuman monoclonal antibody combination"/>
  <result pre="effect of compound glycyrrhizin on SARSChina Pharmacy102003 111WuCXuXLuHAnalysis of the" exact="chest" post="X-ray manifestations in SARS patients treated with compound glycyrrhizinChina"/>
  <result pre="featuresBioorg Med Chem1420068295830610.1016/j.bmc.2006.09.01417046271 116YiLLiZYuanKQuXChenJWangGSmall molecules blocking the entry of severe" exact="acute" post="respiratory syndrome coronavirus into host cellsJ Virol782004113341133910.1128/JVI.78.20.11334-11339.200415452254 117ChaiXHuLZhangYHanWLuZKeASpecific ACE2"/>
  <result pre="Med Chem1420068295830610.1016/j.bmc.2006.09.01417046271 116YiLLiZYuanKQuXChenJWangGSmall molecules blocking the entry of severe acute" exact="respiratory" post="syndrome coronavirus into host cellsJ Virol782004113341133910.1128/JVI.78.20.11334-11339.200415452254 117ChaiXHuLZhangYHanWLuZKeASpecific ACE2 expression"/>
  <result pre="Chem1420068295830610.1016/j.bmc.2006.09.01417046271 116YiLLiZYuanKQuXChenJWangGSmall molecules blocking the entry of severe acute respiratory" exact="syndrome" post="coronavirus into host cellsJ Virol782004113341133910.1128/JVI.78.20.11334-11339.200415452254 117ChaiXHuLZhangYHanWLuZKeASpecific ACE2 expression in"/>
 </snippets>
</snippetsTree>
